{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T19:40:07Z","timestamp":1751053207526,"version":"3.41.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2003,7]]},"DOI":"10.1023\/a:1027355928799","type":"journal-article","created":{"date-parts":[[2003,11,9]],"date-time":"2003-11-09T22:46:39Z","timestamp":1068417999000},"page":"361-366","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Statins on Novel Risk Markers"],"prefix":"10.1007","volume":"17","author":[{"given":"Andrea","family":"Cignarella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Bolego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5149501_CR1","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.","journal-title":"Lancet"},{"key":"5149501_CR2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J,Cobbe SM,Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.","journal-title":"N Engl J Med"},{"key":"5149501_CR3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM,Pfeffer MA,Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.","journal-title":"N Engl J Med"},{"key":"5149501_CR4","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR,Clearfield M,Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS\/ TexCAPS. JAMA 1998; 279: 1615-1622.","journal-title":"JAMA"},{"key":"5149501_CR5","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group","year":"1998","unstructured":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.","journal-title":"N Engl J Med"},{"key":"5149501_CR6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebocontrolled trial. Lancet 2002; 360: 7-22.","journal-title":"Lancet"},{"key":"5149501_CR7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1185\/030079902125000787","volume":"18","author":"VG Athyros","year":"2002","unstructured":"Athyros VG,Papageorgiou AA,Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention: TheGREekAtorvastatin and Impact of Statins on Novel Risk Markers\n365 Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-228.","journal-title":"Curr Med Res Opin"},{"key":"5149501_CR8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/07853890008998823","volume":"32","author":"S Bellosta","year":"2000","unstructured":"Bellosta S,Ferri N,Bernini F,Paoletti R,Corsini A. Nonlipid-related effects of statins. Ann Med 2000; 32: 164-176.","journal-title":"Ann Med"},{"key":"5149501_CR9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0002-9149(01)02257-3","volume":"89","author":"S Sasaki","year":"2002","unstructured":"Sasaki S,Kuwahara N,Kunitomo K, et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 2002; 89: 386-389.","journal-title":"Am J Cardiol"},{"key":"5149501_CR10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0002-9149(01)01639-3","volume":"88","author":"JM McKenney","year":"2001","unstructured":"McKenney JM,McCormick LS,Schaefer EJ,Black DM,Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001; 88: 270-274.","journal-title":"Am J Cardiol"},{"key":"5149501_CR11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/01.ATV.20.1.189","volume":"20","author":"M Guerin","year":"2000","unstructured":"Guerin M,Lassel TS,Le Goff W,Farnier M,Chapman MJ. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000; 20: 189-197.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5149501_CR12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0021-9150(02)00037-0","volume":"163","author":"M Guerin","year":"2002","unstructured":"Guerin M,Egger P,Soudant C, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: Preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 2002; 163: 287-296.","journal-title":"Atherosclerosis"},{"key":"5149501_CR13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1053\/meta.2002.30510","volume":"51","author":"L Pontrelli","year":"2002","unstructured":"Pontrelli L,Parris W,Adeli K,Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose\/ type 2 diabetes. Metabolism 2002; 51: 334-342.","journal-title":"Metabolism"},{"key":"5149501_CR14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0021-9150(02)00149-1","volume":"164","author":"BF Asztalos","year":"2002","unstructured":"Asztalos BF,Horvath KV,McNamara JR,Roheim PS,Rubinstein JJ,Schaefer EJ. Comparing the effects of five different statins on theHDLsubpopulation profiles of coronary heart disease patients. Atherosclerosis 2002; 164: 361-369.","journal-title":"Atherosclerosis"},{"key":"5149501_CR15","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1194\/jlr.M200037-JLR200","volume":"43","author":"BF Asztalos","year":"2002","unstructured":"Asztalos BF,Horvath KV,McNamara JR,Roheim PS,Rubinstein JJ,Schaefer EJ. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 2002; 43: 1701-1707.","journal-title":"J Lipid Res"},{"key":"5149501_CR16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0735-1097(00)01126-8","volume":"37","author":"A von Eckardstein","year":"2001","unstructured":"von Eckardstein A,Schulte H,Cullen P,Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37: 434-439.","journal-title":"J Am Coll Cardiol"},{"key":"5149501_CR17","unstructured":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Available at: http:\/\/www.nhlbi.nih.gov\/guidelines\/cholesterol\/atp3full.pdf"},{"key":"5149501_CR18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0021-9150(02)00072-2","volume":"164","author":"S Gonbert","year":"2002","unstructured":"Gonbert S,Malinsky S,Sposito AC, et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002; 164: 305-311.","journal-title":"Atherosclerosis"},{"key":"5149501_CR19","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1006\/bbrc.2001.6066","volume":"289","author":"D Teupser","year":"2001","unstructured":"Teupser D,Bruegel M,Stein O,Stein Y,Thiery J. HMGCoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells. Biochem Biophys Res Commun 2001; 289: 838-844.","journal-title":"Biochem Biophys Res Commun"},{"key":"5149501_CR20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/01.RES.0000028454.42385.8B","volume":"91","author":"A Kawakami","year":"2002","unstructured":"Kawakami A,Tanaka A,Nakajima K,Shimokado K,Yoshida M. Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions. Circ Res 2002; 91: 263-271.","journal-title":"Circ Res"},{"key":"5149501_CR21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0021-9150(01)00696-7","volume":"162","author":"I Seljeflot","year":"2002","unstructured":"Seljeflot I,Tonstad S,Hjermann I,Arnesen H. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 2002; 162: 179-185.","journal-title":"Atherosclerosis"},{"key":"5149501_CR22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0735-1097(00)00743-9","volume":"36","author":"MJ Mullen","year":"2000","unstructured":"Mullen MJ,Wright D,Donald AE,Thorne S,Thomson H,Deanfield JE. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: A doubleblind study. J Am Coll Cardiol 2000; 36: 410-416.","journal-title":"J Am Coll Cardiol"},{"key":"5149501_CR23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1210\/jcem.87.2.8249","volume":"87","author":"KC Tan","year":"2002","unstructured":"Tan KC,Chow WS,Tam SC,Ai VH,Lam CH,Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87: 563-568.","journal-title":"J Clin Endocrinol Metab"},{"key":"5149501_CR24","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/diacare.24.8.1335","volume":"24","author":"The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group","year":"2001","unstructured":"The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia-The DALI study: A double-blind, randomized, placebocontrolled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001; 24: 1335-1341.","journal-title":"Diabetes Care"},{"key":"5149501_CR25","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2337\/diacare.25.7.1211","volume":"25","author":"FV van Venrooij","year":"2002","unstructured":"van Venrooij FV,van de Ree MA,Bots ML,Stolk RP,Huisman MV,Banga JD. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes-The Diabetes Atorvastatin Lipid Intervention (DALI) Study: A randomized, double-blind, placebo-controlled trial. Diabetes Care 2002; 25: 1211-1216.","journal-title":"Diabetes Care"},{"key":"5149501_CR26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/01.ATV.0000015330.64968.C4","volume":"22","author":"RW van Etten","year":"2002","unstructured":"van Etten RW,de Koning EJP,Honing ML,Stroes ES,Gaillard CA,Rabelink TJ. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2002; 22: 799-804.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5149501_CR27","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1161\/01.CIR.0000027569.76671.A8","volume":"106","author":"A Ceriello","year":"2002","unstructured":"Ceriello A,Taboga C,Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short-and long-term simvastatin treatment. Circulation 2002; 106: 1211-1218.","journal-title":"Circulation"},{"key":"5149501_CR28","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1161\/01.CIR.0000018166.84319.55","volume":"105","author":"DH Walter","year":"2002","unstructured":"Walter DH,Rittig K,Bahlmann FH, et al. Statin therapy accelerates reendothelialization:Anovel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017-3024.","journal-title":"Circulation"},{"key":"5149501_CR29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R. Ross","year":"1999","unstructured":"Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.","journal-title":"N Engl J Med"},{"key":"5149501_CR30","doi-asserted-by":"crossref","first-page":"13043","DOI":"10.1073\/pnas.192399699","volume":"99","author":"MK Chang","year":"2002","unstructured":"Chang MK,Binder CJ,Torzewski M,Witztum JL. Creactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002; 99: 13043-13048.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5149501_CR31","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1161\/01.CIR.103.13.1813","volume":"103","author":"PM. Ridker","year":"2001","unstructured":"Ridker PM. High sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.","journal-title":"Circulation"},{"key":"5149501_CR32","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/diabetes.51.4.1131","volume":"51","author":"A Festa","year":"2002","unstructured":"Festa A,D'Agostino R Jr,Tracy RP,Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 1131-1137.","journal-title":"Diabetes"},{"key":"5149501_CR33","doi-asserted-by":"crossref","unstructured":"Devaraj S,Xu DY,Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107:398-404.","DOI":"10.1161\/01.CIR.0000052617.91920.FD"},{"key":"5149501_CR34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bjp.0704678","volume":"136","author":"AH Wagner","year":"2002","unstructured":"Wagner AH,Schwabe O,Hecker M. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 2002; 136: 143-149.","journal-title":"Br J Pharmacol"},{"key":"5149501_CR35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1365-2796.2002.00966.x","volume":"251","author":"O Wiklund","year":"2002","unstructured":"Wiklund O,Mattsson-Hult\u00e9n L,Hurt-Camejo E,Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 2002; 251: 338-347.","journal-title":"J Intern Med"},{"key":"5149501_CR36","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.103.15.1933","volume":"103","author":"I Jialal","year":"2001","unstructured":"Jialal I,Stein D,Balis D,Grundy SM,Adams-Huet B,Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-1935.","journal-title":"Circulation"},{"key":"5149501_CR37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0021-9150(02)00316-7","volume":"166","author":"MA van de Ree","year":"2003","unstructured":"van de Ree MA,Huisman MV,Princen HMG,Meinders AE,Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129-135.","journal-title":"Atherosclerosis"},{"key":"5149501_CR38","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/01.CIR.0000029743.68247.31","volume":"106","author":"JK Plenge","year":"2002","unstructured":"Plenge JK,Hernandez TL,Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106: 1447-1452.","journal-title":"Circulation"},{"key":"5149501_CR39","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1053\/euhj.2001.2967","volume":"23","author":"WF Riesen","year":"2002","unstructured":"Riesen WF,Engler H,Risch M,Korte W,Noseda G. Shortterm effects of atorvastatin on C-reactive protein. Eur Heart J 2002; 23: 794-799.","journal-title":"Eur Heart J"},{"key":"5149501_CR40","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/01.ATV.0000012802.69414.A8","volume":"22","author":"R Baetta","year":"2002","unstructured":"Baetta R,Camera M,Comparato C,Altana C,Ezekowitz MD,Tremoli E. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2002; 22: 692-698.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5149501_CR41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-0037-1613151","volume":"88","author":"M Cortellaro","year":"2002","unstructured":"Cortellaro M,Cofrancesco E,Arbustini E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: The ATROCAP study. Thromb Haemost 2002; 88: 41-47.","journal-title":"Thromb Haemost"},{"key":"5149501_CR42","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-128-4-199802150-00002","volume":"128","author":"HN Hodis","year":"1998","unstructured":"Hodis HN,Mack WJ,LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262-269.","journal-title":"Ann Intern Med"},{"key":"5149501_CR43","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/01.STR.31.10.2426","volume":"31","author":"D Baldassarre","year":"2000","unstructured":"Baldassarre D,Amato M,Bondioli A,Sirtori CR,Tremoli E. Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors. Stroke 2000; 31: 2426-2430.","journal-title":"Stroke"},{"key":"5149501_CR44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199901073400103","volume":"340","author":"DH O'Leary","year":"1999","unstructured":"O'Leary DH,Polak JF,Kronmal RA,Manolio TA,Burke GL,Wolfson SKJr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22.","journal-title":"N Engl J Med"},{"key":"5149501_CR45","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0002-9343(96)00333-6","volume":"101","author":"M Mercuri","year":"1996","unstructured":"Mercuri M,Bond MG,Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101: 627-634.","journal-title":"Am J Med"},{"key":"5149501_CR46","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0021-9150(99)00434-7","volume":"151","author":"D Baldassarre","year":"2000","unstructured":"Baldassarre D,Veglia F,Gobbi C, et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: The Carotid Atherosclerosis Italian Ultrasound Study. Atherosclerosis 2000; 151: 575-583.","journal-title":"Atherosclerosis"},{"key":"5149501_CR47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/ejvs.2002.1611","volume":"23","author":"F Youssef","year":"2002","unstructured":"Youssef F,Seifalian AM,Jagroop IA, et al. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 2002; 23: 358-364.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"5149501_CR48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","volume":"357","author":"TJ Smilde","year":"2001","unstructured":"Smilde TJ,van Wissen S,Wollersheim H,Trip MD,Kastelein JJP,Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001; 357: 577-581.","journal-title":"Lancet"},{"key":"5149501_CR49","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","volume":"106","author":"AJ Taylor","year":"2002","unstructured":"Taylor AJ,Kent SM,Flaherty PJ,Coyle LC,Markwood TT,Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055-2060.","journal-title":"Circulation"},{"key":"5149501_CR50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0735-1097(01)01737-5","volume":"39","author":"R Wayhs","year":"2002","unstructured":"Wayhs R,Zelinger A,Raggi P. High coronary artery calcium scores pose an extremely elevated risk for hard events. J Am Coll Cardiol 2002; 39: 225-230.","journal-title":"J Am Coll Cardiol"},{"key":"5149501_CR51","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1067\/mhj.2001.114372","volume":"141","author":"P Raggi","year":"2001","unstructured":"Raggi P,Callister TQ,Davidson M, et al. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J 2001; 141: 722-726.","journal-title":"Am Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1027355928799.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1027355928799\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1027355928799.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T19:08:32Z","timestamp":1751051312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1027355928799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["5149501"],"URL":"https:\/\/doi.org\/10.1023\/a:1027355928799","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}